Skip to main content
VISIT JANSSEN GLOBAL
 
 
 

UK
change location▼

Search
Search

Welcome to Janssen UK

Visit Janssen Global

Media Centre

The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree Cancel

Press Releases

12, July, 2023

New Data from the Phase IIIb ESCAPE-TRD Study Show SPRAVATO®▼ (Esketamine Nasal Spray [NS]) Improves Rate and Time to Remission versus Quetiapine Extended-Release in Patients with Treatment-Resistant Depression and Two or Three Plus Prior Treatment Failures

13, December, 2022

Risk of complications and comorbidity higher in South Asian and Black cancer patients compared with population averages across England1

02, December, 2022

Janssen response to the National Institute for Health and Care Excellence (NICE) negative Final Appraisal Document (FAD) for Darzalex® (daratumumab) in combination with bortezomib, cyclophosphamide and dexamethasone (DBCd) for the treatment of adult patients with newly diagnosed systemic amyloid light-chain (AL) amyloidosis [ID3748]

23, November, 2022

SPRAVATO®▼ (esketamine) nasal spray data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1

27, May, 2022

Janssen Responds to NICE Assessment for SPRAVATO®▼ (Esketamine) Nasal Spray for Treatment-Resistant Major Depressive Disorder

01, February, 2022

BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) Authorised in Great Britain for the Maintenance Treatment of Schizophrenia in Adults

View more Press Releases

Quick Links

 

FOLLOW US

 

Twitter

Follow us on Twitter